SSTR antagonists have been shown to lead to higher tumour dose and tumour‐to‐organ ratios than agonists in pre‐clinical research, due to their capability to bind to the SSTR2 in its active and inactive states. The gene discussed is SSTR2; the disease is neoplasm.